Fig. 2

Seropositivity anti-SARS-CoV-2 spike protein before and after the first and second dose of the vaccine CoronaVac. Health Care services volunteers from study group 1 received a complete CoronaVac vaccination scheme. Serum samples were collected as indicated: Pre-Vax, prior to the first dose, first dose +30d, 30 days after the first dose, second dose +30d, 30 days after the second dose. A Data from 104 volunteers are shown before vaccination, 30 days after the first, and 30 days after the second dose. The gray circles show the values of people who may have contracted the disease before vaccination (AUC > 300). Black circles are from the other 86 samples being negative or weakly positive. B Data shown in A were disaggregated into three groups within AUC values before vaccination: 18 Individuals with an AUC > 300 (positive) are shown in orange, 26 with an AUC 120–300 in green, and 60 individuals AUC < 120 in blue. C Serum neutralization capacity in vaccinated participants 30 days after the second dose was correlated with correspondent AUC. Each dot represents a single serum sample. ****p < .0001, ***p < .001, *p < .05